pureMHC Overview

  • Founded
  • 2003
  • Status
  • Private
  • Latest Deal Type
  • Early Stage VC
  • Latest Deal Amount
  • $2M
Latest Deal Amount
  • Investors
  • 2

pureMHC General Information


Provider of a technology platform intended to be used for disease-specific target identification. The company's platform develops antibodies that mimic the specificity of T-cell receptors in the immune system, enabling healthcare practitioners to avail breakthrough therapeutic target discovery and validation with further drug development applications.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Other Industries
Drug Discovery
Primary Office
  • 7500 Rialto Boulevard
  • Building 2, Suite 260
  • Austin, TX 78735
  • United States
+1 (512) 000-0000
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

pureMHC Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
1. Early Stage VC 18-Jun-2008 $2M 000 Completed Generating Revenue
To view pureMHC’s complete valuation and funding history, request access »

pureMHC Executive Team (5)

Name Title Board Seat Contact Info
Jane Yacuik Ph.D Director, Operations
William Hildebrand Ph.D Co-Founder and Chief Scientist – Target Discovery
Thomas Harlan Chief Executive Officer
To view pureMHC’s complete executive team members history, request access »

pureMHC Investors (2)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
Emergent Technologies VC-Backed Company Minority 000 0000 000000 0
Texas Emerging Technology Fund Venture Capital Minority 000 0000 000000 0
To view pureMHC’s complete investors history, request access »